癌症检测产品供应商Grail(GRAL.US)今晚登陆纳斯达克已从Illumina(ILMN.US)剥离

智通财经06-25

智通财经APP获悉，从生命科学公司Illumina(ILMN.US)分拆出来的癌症检测产品供应商Grail(GRAL.US)于周二在纳斯达克上市。据悉，Illumina于2020年9月收购 Grail。据交易公告，Illumina会为Grail提供80亿美元现金和股票。但由于改交易有潜在的反垄断违规行为，所以很快遭到监管机构强烈抵制。在美国，联邦贸易委员会于2021年3月提出申诉，阻止此次收购。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2446849326?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-25 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446849326","market":"sh","top_or_hot":-1,"title":"癌症检测产品供应商Grail(GRAL.US)今晚登陆纳斯达克 已从Illumina(ILMN.US)剥离","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，从生命科学公司Illumina(ILMN.US)分拆出来的癌症检测产品供应商Grail(GRAL.US)于周二在纳斯达克上市。据悉，Illumina于2020年9月收购 Grail。据交易公告，Illumina会为Grail提供80亿美元现金和股票。但由于改交易有潜在的反垄断违规行为，所以很快遭到监管机构强烈抵制。在美国，联邦贸易委员会于2021年3月提出申诉，阻止此次收购。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1140439.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>癌症检测产品供应商Grail(GRAL.US)今晚登陆纳斯达克 已从Illumina(ILMN.US)剥离</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n癌症检测产品供应商Grail(GRAL.US)今晚登陆纳斯达克 已从Illumina(ILMN.US)剥离\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-25 21:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1140439.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，从生命科学公司Illumina(ILMN.US)分拆出来的癌症检测产品供应商Grail(GRAL.US)于周二在纳斯达克上市。据悉，Illumina于2020年9月收购 Grail。据交易公告，Illumina会为Grail提供80亿美元现金和股票。但由于改交易有潜在的反垄断违规行为，所以很快遭到监管机构强烈抵制。在美国，联邦贸易委员会于2021年3月提出申诉，阻止此次收购。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1140439.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":".IXIC","symbol_name":"NASDAQ Composite","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1140439.html","article_id":"2446849326","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446849326","pubTimestamp":1719322035,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，从生命科学公司Illumina分拆出来的癌症检测产品供应商Grail于周二在纳斯达克上市。据悉，Illumina于2020年9月收购 Grail。据交易公告，Illumina会为Grail提供80亿美元现金和股票。今年4月，Illumina剥离/被迫放弃收购Grail的计划获得欧盟委员会正式批准。本月早些时候，Illumina宣布其董事会已批准Grail的分拆流程，预计Grail将于6月24日从Illumina分拆出来。此外，Illumina董事会宣布将保留Grail 14.5%的股权，剩余的至少85.5%股份将被无偿的分配给Illumina的全体股东。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159632":"纳斯达克",".IXIC":"NASDAQ Composite","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK1147":"投资银行业与经纪业","QLD":"纳指两倍做多ETF","BK4007":"制药","ARTL":"Artelo Biosciences, Inc.","QID":"纳指两倍做空ETF","BK4535":"淡马锡持仓","BK4121":"生命科学工具和服务","BK4588":"碎股","TQQQ":"纳指三倍做多ETF","SQQQ":"纳指三倍做空ETF","ILMN":"Illumina","03086":"华夏纳指","NDX":"纳斯达克100指数","BK4548":"巴美列捷福持仓","PSQ":"纳指反向ETF","QQQ":"纳指100ETF"},"translate_title":"Cancer detection product supplier Grail (GRAL.US) landed on Nasdaq tonight and has been spun off from Illumina (ILMN.US)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159632":1,"03086":1,"ARTL":1,".IXIC":1,"NDX":1,"ILMN":1,"TQQQ":0.6,"SQQQ":0.6,"QQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"智通财经APP获悉，从生命科学公司Illumina(ILMN.US)分拆出来的癌症检测产品供应商Grail(GRAL.US)于周二在纳斯达克上市。据悉，Illumina于2020年9月收购 Grail。据交易公告，Illumina会为Grail提供80亿美元现金和股票。但由于改交易有潜在的反垄断违规行为，所以很快遭到监管机构强烈抵制。在美国，联邦贸易委员会于2021年3月提出申诉，阻止此次收购。2021年7月，欧盟对拟议收购启动调查。Illumina和Grail在调查仍在进行时完成了交易，这迫使欧盟委员会于2021年10月采取临时措施，确保两家公司在调查结果出来之前仍然是独立的实体的调查。最终，欧盟委员会于2022年9月禁止了此次收购，并于去年12月告诉Illumina必须“取消对Grail的收购”，以使禁令全面生效。今年4月，Illumina剥离/被迫放弃收购Grail的计划获得欧盟委员会正式批准。本月早些时候，Illumina宣布其董事会已批准Grail的分拆流程，预计Grail将于6月24日从Illumina分拆出来。此外，Illumina董事会宣布将保留Grail 14.5%的股权(这是欧盟允许的上限)，剩余的至少85.5%股份将被无偿的分配给Illumina的全体股东。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446849326"}

癌症检测产品供应商Grail(GRAL.US)今晚登陆纳斯达克 已从Illumina(ILMN.US)剥离

精彩评论

癌症检测产品供应商Grail(GRAL.US)今晚登陆纳斯达克已从Illumina(ILMN.US)剥离